CloneID: FAP2M21
Heavy Chain modification: Fc Silent™
Antigen Long Description: The original antibody was generated by panning a fully human scFv phage display library with recombinant human PCSK9. Later on the scFv was transformed into a full length IgG antibody.
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This is a reformatted mouse IgG2a Fc Silent™ antibody, based on the original mouse IgG1 format, created for improved compatibility with existing reagents, assays and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: Q8NBP7
Specificity Statement: This antibody specifically binds the module 2 (amino acid residues 530-605) of the C-terminal domain (CTD) of PCSK9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease enzyme encoded by the PCSK9 gene in humans and it plays a role in regulation of circulating cholesterol. It is associated with autosomal dominant hypercholesterolemia, a state of elevated levels of LDL (low-density lipoprotein) cholesterol. Autosomal dominant hypercholesterolemia can result in severe implications such as stroke and coronary heart disease.
Application Notes (Clone): This antibody binds human PCSK9 with an extremely slow dissociation rate constant and exert its hypolipidemic effect by blocking PCSK9-LDLR interaction. The binding characterization of this antibody was done using ELISA. Bio-Layer Interferometry (BLI) analysis revealed that the full-length IgG1 antibody FAP2M21 binds to hPCSK9 with a KD as low as 1.42 nM, and a dramatically slow dissociation rate (koff, 4.68 × 10−6 s−1) (PMID: 33647772). This antibody was also used to analyze LDLR expressed on the surface of HepG2 cells using flow cytometry and immunofluorescence staining. This antibody potently inhibited PCSK9-induced reduction of LDL-C uptake in HepG2 cells, with an EC50 of 43.56 nM. When this antibody was injected in C57BL/6 mice expressing human PCSK9, it dose-dependently up-regulated hepatic LDLR levels, and concomitantly reduced serum LDL-C by 3.3% and 37.2%, respectively (PMID: 33647772).
English
Deutsch
